
CLPT Stock Forecast & Price Target
CLPT Analyst Ratings
Bulls say
ClearPoint Neuro Inc. is positioned for a strong future, demonstrating a solid foundation with a reported 17% topline growth in 2023, alongside a significant reduction in cash burn. The company is expected to see at least 20% revenue growth in 2024, driven by an expanding partnership base and enhanced service offerings in its Biologics division. Additionally, the momentum gained in 2024 through key product approvals and record system installations showcases ClearPoint Neuro's ability to innovate and capture market share, further supporting a favorable outlook for the company's financial prospects.
Bears say
ClearPoint Neuro Inc has demonstrated a significant reduction in cash burn, decreasing from $5.8 million in the first quarter of 2023 to $1.2 million in the fourth quarter, indicating improved financial management. However, despite this positive trend in cash burn, the overall financial health remains a concern due to the company's reliance on this singular metric without substantial revenue growth reported to ensure sustainability. Furthermore, the company's ongoing need to further decrease cash burn in 2024 raises questions about its operational viability and ability to invest in future growth initiatives.
This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.
CLPT Analyst Forecast & Price Prediction
Start investing in CLPT
Order type
Buy in
Order amount
Est. shares
0 shares